Low-Dose Pioglitazone does not Increase ROS Production in Chronic Granulomatous Disease Patients with Severe Infection.

doi:10.1007/s10875-019-00719-z

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Low-Dose Pioglitazone does not Increase ROS Production in Chronic Granulomatous Disease Patients with Severe Infection.

Journal of clinical immunology - 1 Jan 2020

Hui Xiaoying, Liu Danru, Wang Wenjie, Hou Jia, Ying Wenjing, Zhou Qinhua, Yao Haili, Sun Jinqiao, Wang Xiaochuan

Abstract excerpt

PURPOSE: We sought to further investigate the efficacy and safety of pioglitazone for chronic granulomatous disease (CGD) patients with severe infection. METHODS: CGD patients with severe infection were enrolled and treated with pioglitazone for 90 days. The degree of improvement in infection and the changes of dihydrorhodamine-123 (DHR) were used to evaluate the efficacy of pioglitazone. The adverse reaction of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Child, Preschool
Share to Granulomatous Disease, Chronic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to NADPH Oxidase 2

Share to NADPH Oxidases

Share to Pioglitazone

Share to Reactive Oxygen Species

Share to Rhodamines

Source

Open in PubMed

Identifiers

PMID: 31745699
DOI: 10.1007/s10875-019-00719-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.